Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression

Ni,Beibei; Hu,Jun; Chen,Dianke; Li,Li; Chen,Daici; Wang,Jianping; Wang,Lei

doi:10.3892/ol.2016.4858

Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression

Authors:
- Beibei Ni
- Jun Hu
- Dianke Chen
- Li Li
- Daici Chen
- Jianping Wang
- Lei Wang
View Affiliations

Affiliations: Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China, Guangdong Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China
Published online on: July 13, 2016 https://doi.org/10.3892/ol.2016.4858
Pages: 1737-1744
Copyright: © Ni et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Spleen tyrosine kinase (SYK) has been reported as a potential tumor suppressor in colorectal cancer (CRC). However, the role of alternative splicing of SYK in carcinogenesis remains unclear. In the present study, SYK isoforms were overexpressed in the human CRC HCT 116 cell line using lentiviral expression vectors to investigate the biological functions of full length SYK [SYK(L)] and short form SYK [SYK(S)] in CRC. Real-time cellular analysis and the 5-ethynyl-2-deoxyuridine assay were used to detect the effects of SYK(L) and SYK(S) on cell proliferation. Cell cycle progression and migration were assessed via flow cytometry and Transwell assays, respectively. The results revealed that the recombinant lentivirus with SYK(L) overexpression significantly suppressed the proliferation and metastasis of CRC cells, while SYK(S) overexpression did not. In addition, MTS assays demonstrated that SYK(L) and SYK(S) increased the cellular sensitivity to 5-fluorouracil (5-FU), suggesting that SYK(L) and 5-FU produce a significant synergistic effect on CRC cell proliferation, while SYK(S) has an effect on modulating CRC 5‑FU sensitivity. Furthermore, quantitative polymerase chain reaction results revealed that SYK(L) was downregulated in 69% of 26 pairs of CRC and adjacent non‑cancerous tissues, whereas SYK(S) exhibited no significant differences between tumor and normal tissues. Overall, the present data provides evidence that SYK(L) is a tumor suppressor in CRC, and both SYK(L) and SYK(S) may serve as important predictors in the chemotherapeutic treatment of CRC.

View Figures

View References

1	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
2	Guo P, Huang ZL, Yu P and Li K: Trends in cancer mortality in China: An update. Ann Oncol. 23:2755–2762. 2012. View Article : Google Scholar : PubMed/NCBI
3	Grädler U, Schwarz D, Dresing V, Musil D, Bomke J, Frech M, Greiner H, Jäkel S, Rysiok T, Müller-Pompalla D and Wegener A: Structural and biophysical characterization of the Syk activation switch. J Mol Biol. 425:309–333. 2013. View Article : Google Scholar : PubMed/NCBI
4	Coopman PJ and Mueller SC: The Syk tyrosine kinase: A new negative regulator in tumor growth and progression. Cancer Lett. 241:159–173. 2006. View Article : Google Scholar : PubMed/NCBI
5	Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH and Mueller SC: The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 406:742–747. 2000. View Article : Google Scholar : PubMed/NCBI
6	Wang L, Devarajan E, He J, Reddy SP and Dai JL: Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 65:10289–10297. 2005. View Article : Google Scholar : PubMed/NCBI
7	Zhang X, Shrikhande U, Alicie BM, Zhou Q and Geahlen RL: Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res. 7:634–644. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ogane S, Onda T, Takano N, Yajima T, Uchiyama T and Shibahara T: Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma. Int J Cancer. 124:2651–2657. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, et al: CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest. 122:2165–2175. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nakashima H, Natsugoe S, Ishigami S, Okumura H, Matsumoto M, Hokita S and Aikou T: Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett. 236:89–94. 2006. View Article : Google Scholar : PubMed/NCBI
11	Peng C, Sun Q, Hao Y, Cong B, Zhao Y and Zhao X: Syk is low-expressed in non-small-cell lung cancer and inversely correlates with patient's survival. Acta Bioch Biophys Sin (Shanghai). 45:149–151. 2013. View Article : Google Scholar
12	Yang Z, Huo L, Chen H, Ni B, Xiang J, Kang L, Wang L, Peng J, Yuan Y and Wang J: Hypermethylation and prognostic implication of Syk gene in human colorectal cancer. Med Oncol. 30:2013. View Article : Google Scholar
13	Layton T, Stalens C, Gunderson F, Goodison S and Sillett S: Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am J Pathol. 175:2625–2636. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yuan YF, Wang JP, Li JP, Wang L, Li M, Yang Z, Zhang C and Dai JL: Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res. 12:6687–6695. 2006. View Article : Google Scholar : PubMed/NCBI
15	Peng CL, Zhang Y, Sun QF, Zhao YP, Hao YT, Zhao XG and Cong B: Inhibitory effects of Syk transfection on lung cancer cell invasion. Asian Pac J Cancer Prev. 14:3001–3003. 2013. View Article : Google Scholar : PubMed/NCBI
16	Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, Rhŷs-Evans P, O-charoenrat P and Eccles S: Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res. 67:7907–7916. 2007. View Article : Google Scholar : PubMed/NCBI
17	Du ZM, Kou CW, Wang HY, Huang MY, Liao DZ, Hu CF, Chen J, Yan LX, Hu LF, Ernberg I, et al: Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma. Head Neck. 34:1456–1464. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R and Dai JL: Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 63:4724–4730. 2003.PubMed/NCBI
19	Hong J, Yuan YF, Wang JP, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, et al: Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res. 74:1845–1856. 2014. View Article : Google Scholar : PubMed/NCBI
20	Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, et al: Alternative splicing of SYK regulates mitosis and cell survival. Nat Struct Mol Biol. 18:673–679. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yuan Y, Mendez R, Sahin A and Dai JL: Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61:5558–5561. 2001.PubMed/NCBI
22	Yan C, Liu C, Jin Q, Li Z, Tao B and Cai Z: The promoter methylation of the Syk gene in nasopharyngeal carcinoma cell lines. Oncol Lett. 4:505–508. 2012.PubMed/NCBI
23	Shin SH, Lee KH, Kim BH, Lee S, Lee HS, Jang JJ and Kang GH: Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis. Lab Invest. 94:1396–1405. 2014. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Davies JM and Goldberg RM: Treatment of metastatic colorectal cancer. Semin Oncol. 38:552–560. 2011. View Article : Google Scholar : PubMed/NCBI
26	Shen L, Yu M, Xu X, Gao L, Ni J, Luo Z and Wu S: Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine-type N-glycans. Int J Oncol. 45:2560–2568. 2014.PubMed/NCBI
27	Ladomery M: Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013:4637862013. View Article : Google Scholar : PubMed/NCBI
28	Hatakeyama K, Wakabayashi-Nakao K, Ohshima K, Sakura N, Yamaguchi K and Mochizuki T: Novel protein isoforms of carcinoembryonic antigen are secreted from pancreatic, gastric and colorectal cancer cells. BMC Res Notes. 6:3812013. View Article : Google Scholar : PubMed/NCBI
29	Kahkhaie KR, Moaven O, Abbaszadegan MR, Montazer M and Gholamin M: Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer. World J Surg. 38:2052–2057. 2014. View Article : Google Scholar : PubMed/NCBI
30	Jacob AG, O'Brien D, Singh RK, Comiskey DF Jr, Littleton RM, Mohammad F, Gladman JT, Widmann MC, Jeyaraj SC, Bolinger C, et al: Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma. Neoplasia. 15:1049–1063. 2013. View Article : Google Scholar : PubMed/NCBI
31	Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, et al: Identification of alternative splicing markers for breast cancer. Cancer Res. 68:9525–9531. 2008. View Article : Google Scholar : PubMed/NCBI
32	Miura K, Fujibuchi W and Unno M: Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis. 33:2311–2319. 2012. View Article : Google Scholar : PubMed/NCBI
33	Geahlen RL: Getting Syk: Spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 35:414–422. 2014. View Article : Google Scholar : PubMed/NCBI
34	Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, et al: SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 25:226–242. 2014. View Article : Google Scholar : PubMed/NCBI
35	Shakeel S, Mahjabeen I, Kayani MA and Faryal R: Association of SYK genetic variations with breast cancer pathogenesis. Asian Pac J Cancer Prev. 14:3309–3314. 2013. View Article : Google Scholar : PubMed/NCBI
36	Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ and Burger JA: Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 26:1576–1583. 2012. View Article : Google Scholar : PubMed/NCBI
37	Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP, Ballotti R, et al: Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res. 69:2748–2756. 2009. View Article : Google Scholar : PubMed/NCBI
38	Sung YM, Xu X, Sun J, Mueller D, Sentissi K, Johnson P, Urbach E, Seillier-Moiseiwitsch F, Johnson MD and Mueller SC: Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One. 4:e74452009. View Article : Google Scholar : PubMed/NCBI
39	Larive RM, Urbach S, Poncet J, Jouin P, Mascré G, Sahuquet A, Mangeat PH, Coopman PJ and Bettache N: Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene. 28:2337–2347. 2009. View Article : Google Scholar : PubMed/NCBI